Effect of Ambroxol in Diabetic Peripheral Neuropathy

• Status: Not yet recruiting
• Trial end date: 2023-11-01
• Target enrollment: 0
• Participant gender: All

Summary

A prospective, randomized, controlled study will be conducted at Department of Endocrinology, Faculty of Medicine, Ain Shams University, assessing the efficacy of Ambroxol addition on the clinical outcome and inflammatory markers in Diabetic peripheral neuropathy patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Ambroxol

Criteria

Inclusion Criteria:

• Patients aged 18-75 years diagnosed with Type 2 Diabetes.

• Patients diagnosed with Peripheral Diabetic Neuropathy.

Exclusion Criteria:

• Patients with autoimmune disorders (Sjogren's syndrome, lupus, rheumatoid arthritis),inherited disorders causing PN (Charcot-Marie-Tooth), thyroid diseases, patients undergone gastroplasty surgery and cancer patients.

• Pressure on or injury to the nerves

• Patients with severe kidney or liver dysfunction.

• Patients with recent history of / or ongoing infection.

• Patients with cerebral vascular disease, vasculitis, peripheral arterial disease or claudication symptoms, toxic neuritis, vitamin B12 or folate deficiency, spondyloarthropathy, foot edema or ulcer and diagnosis of other neuromuscular disorders or neurodegenerative diseases.

• Use of medications or supplements known to cause peripheral neuropathy.

• Patients consuming alcohol, any antioxidant supplements or anti-inflammatory medicines and drug abuse.

• Ketoacidosis or hypoglycemia resulting in hospital admission within the last 3 months.

• Pregnancy or lactation or expecting to get pregnant during the study.

• Medical, psychological, behavioral or pharmacological factors interfering with ability to participate in trial, collection or interpretation of study data.

• Allergy to ambroxol.